Objective: To evaluate the frequency of HIV-associated neurocognitive disorder (HAND) in HIV1 individuals and determine whether the frequency of HAND changed over 4 years of follow-up.
MND remain high among participants in the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort. 2 The question arises whether HAND continues to be a progressive neurologic syndrome as it was in the pre-cART era, particularly given that the HIV1 population is living longer and subject to age-associated conditions, which themselves can lead to greater risk of cognitive impairment. The objectives of this study were to (1) evaluate the frequency of HAND in HIV1 individuals in the Multicenter AIDS Cohort Study (MACS) and (2) determine whether the frequency of HAND changed over a 4-year period of follow-up. METHODS Research participants. The study was conducted within the MACS, a study of HIV infection among gay/bisexual men. 4 Participants undergo an interview and clinical assessment including an evaluation of psychomotor speed performance every 6 months and a neuropsychological test battery administered to HIV1 individuals biannually. An instrumental activities of daily living (IADL) scale 5 was also administered at each visit beginning in 2007, allowing for the classification of HAND.
HIV1 participants with confounding conditions likely to contribute to cognitive impairment were excluded from the analysis. These included any history of brain opportunistic infections, non-HIV-associated neurologic disease, history of major psychiatric disorder, current alcohol or substance dependence, collagen vascular disease, thyroid disease, chronic obstructive pulmonary disease, congestive heart failure, angina pectoris, myocardial infarction within the prior 6 months, hepatic failure, renal failure, daily use of systemic steroids, narcotic/opioid analgesics, or immunostimulant/immunosuppressive medications.
Standard protocol approvals, registrations, and patient consents. An institutional review board/ethical standards committee approved the use of human subjects for this study at each site. Written informed consent was obtained from all participants.
HAND classification in the MACS. Diagnoses of HAND
were operationalized using criteria outlined previously. 3, 6 The HAND classification system requires (1) cognitive testing, (2) an index of activities of daily living, and (3) medical history and testing to rule out alternative diagnoses. was derived by averaging the 2 T scores or, in the case of the motor domain, using the lowest T score on either the dominant or nondominant hand of the Grooved Pegboard. If only one test in a domain was completed, 6 the T score for that test was used. Following the procedures described previously, if the T score for one of the tests was $40 and one was ,40, then the domain was assigned the lowest obtained T score plus 5. A global index of cognitive functioning was derived for individuals who had T scores for at least 4 of the 6 cognitive domains. Using the 2007 criteria, 3 cognitive scores were assigned as follows: (1) within normal limits if one or fewer domains had T scores 1 SD or more below the mean;
(2) minor cognitive impairment if 2 or more domains had T scores 1 SD or more below the mean, and the individual did not meet criteria for the more severe category 3 that follows; and (3) moderate to severe cognitive impairment if 2 or more domains had T scores 2 SDs or more below the mean, or one domain had a T score 2.5 SDs or more below the mean. 2. Using this classification model, we ran Monte Carlo analyses 7, 8 applying these criteria to 100,000 random datasets constrained by assumptions of normal distributions for each neuropsychological test and intercorrelations based on MACS data from the HIV-negative cohort. We found that, in a random set of individuals in the general population, 78% would be classified as within normal limits, 20% would be classified as minor cognitive impairment, and 3% would be classified as moderate to severe cognitive impairment. These numbers represent baseline frequencies for these classifications that we might reasonably expect in a population of similar uninfected gay/bisexual men.
Activities of daily living: The MACS uses an adaptation of
Lawton and Brody's 5 IADL scale. A global classification of normal, mild impairment, or severe impairment for IADLs was made if at least 14 of the 16 questions on the IADL questionnaire were completed. Severe impairment was defined as major decline on 2 or more questions or major or minor declines on 4 or more questions. Mild impairment was defined as minor decline on 2 or more questions or major or minor declines on 2 or more questions (but not on enough questions to qualify for severe impairment). Individuals who did not meet criteria for major or minor impairment were classified as normal. 4. Medical comorbidity: The MACS collects self-reported medical information from participants every 6 months. A history of vascular risk factors such as hypertension, diabetes, or hypercholesterolemia was defined by a subject self-reporting these conditions. Serious medical conditions are verified through medical charts. After removing study participants with medical conditions that might confound HAND diagnoses, each individual was assigned a HAND diagnosis (see above exclusion criteria) (within normal limits, ANI, MND, or HAD) ( figure 1 ). To evaluate the role that risk factors play in HAND stage progression, individuals were characterized with respect to age (by decade and stratified around 50 years of age), education, HIV duration, CD4 cell count and nadir, plasma HIV RNA (count and detectability), type of cART, site of evaluation, hepatitis C coinfection, and diagnosis of hypertension, diabetes, or hypercholesterolemia. Likelihood of HAND stage progression was modeled using a logistic regression analysis. Odds ratio (OR) and 95% confidence interval (CI) were calculated for each risk factor. RESULTS A total of 364 HIV1 individuals had HAND classifications in the 2007-2008 period. A total of 197 of them were classified during all 3 time periods (2007-2008, 2009-2010, and 2011-2012) . The characteristics for all 364 HIV1 individuals at the baseline visit, the 197 HIV1 individuals seen at all 3 visits, and the 167 HIV1 individuals seen at some but not all of these visits are described in the table. HIV1 individuals who did not attend all 3 periods were older than HIV1 individuals who attended all 3 visits (p 5 0.002). The overall frequency of HAND for the 364 HIV1 individuals was 33%, and each HAND stage was distributed as follows: ANI 14%, MND 14%, HAD 5%. HIV1 individuals who did not attend all 3 time periods had an increased frequency of HAND in 2007-2008 (41%) compared to HIV1 individuals who did attend all 3 time periods (25%) (p 5 0.004).
The overall frequency of all HAND classifications (including ANI, MND, and HAD) for the 197 HIV1 individuals seen at all 3 times during the 2007-2008 period, 2009-2010 period, and 2011-2012 period were 25%, 25%, and 31%. The showing a deterioration in HAND stage (e.g., ANI to MND or dementia), and 15% showing an improvement in HAND stage (e.g., MND to ANI). From 2007-2008 to 2011-2012, 77% of the HIV1 individuals remained at their same HAND stage, whereas 13% showed a deterioration in HAND stage and 10% showed an improvement in HAND stage. From 2009-2010 to 2011-2012, 71% of the HIV1 individuals remained at their same HAND stage, while 15% showed a worsening in HAND stage and 14% showed an improvement in HAND stage. or diagnosis of hypertension or diabetes and risk of HAND stage progression. DISCUSSION The results from this study suggest that HAND is common in HIV1 individuals, mostly on cART with effective systemic virologic suppression. The frequency of HAND was 25%-33% from 2007 to 2012. This frequency of HAND is somewhat lower than the estimates for HAND in other large cohort studies that report a HAND prevalence of 47% excluding severely confounded cases. 9 Our study excluded additional potentially contributing confounders for cognitive impairment and that could account for the lower prevalence rate of HAND. Demographic differences between the MACS and CHARTER cohorts (e.g., the MACS cohort has a higher mean education and the CHARTER cohort includes both men and women) could also account for these differences.
Unlike the pre-cART era, when HIV-associated cognitive impairment was a progressive condition within months, the diagnosis of MND and HAD is not progressive over a 4-year period in individuals with systemic virologic suppression for the majority (70%) of HIV1 individuals. These results are consistent with a prior study in the MACS cohort showing longitudinally preserved psychomotor speed performance in long-term asymptomatic HIV1 individuals with controlled HIV viremia over a 5-year period. 10 An increase in the frequency of ANI was noted in 2011-2012. It remains to be determined whether this increased frequency of ANI persists in subsequent years, and whether this increased frequency is due to HIV itself or agerelated comorbid conditions unrelated to HIV infection.
A study in the CHARTER cohort found that a diagnosis of ANI was associated with an increased risk for progression to MND or HAD compared to HIV1 individuals with normal cognition. 11 In our study, progression from ANI to either a MND or HAD stage was seen in 7/24 (29%) cases in HIV1 individuals over 4 years of follow-up. In contrast, 14/ 24 (58%) HIV1 individuals remained at ANI over 4 years, whereas 3/24 (13%) HIV1 individuals improved from ANI to normal cognition. Also, 18/ 147 (12%) HIV1 individuals with normal cognition progressed to MND or HAD. Thus, a diagnosis of ANI was associated with a 2-fold increased risk of symptomatic HAND (MND or HAD) compared to a diagnosis of normal cognition in HIV1 individuals, which is similar to the results in the CHARTER cohort. The results from the MACS suggest that the majority of HIV1 individuals with ANI stay at the same HAND stage over a 4-year time period and that progression to a more severe HAND stage is only slightly more common than improvement from ANI to normal cognition.
Another longitudinal study from the CHARTER cohort 12 examining neurocognitive decline found that 61% of participants in CHARTER remained stable, 23% declined, and 17% improved over a mean time period of 35 months. These proportions are similar to the 77% of HIV1 individuals who remained stable, 13% who declined, and 10% who showed improvement in HAND stage over 4 years in our study.
Age was associated with increased risk of HAD, but age was not associated with an increased risk for all stages of HAND, and age was not associated with an increased risk of progression in HAND stage. These results suggest that age-related factors may play an important role in advanced stages of HAND (HAD) but may have less of a role in milder stages of HAND such as ANI. However, the proportion of HIV1 individuals $60 years of age was small. Further studies are needed in cohorts with more HIV1 individuals $60 years of age to evaluate the impact of age on HAND.
Even though HAND appears to be a stable clinical diagnosis for the majority of HIV1 individuals in this study (77%), there could still be ongoing CNS damage. Indeed, neuroimaging studies within the MACS suggest that gray matter and white matter atrophy, 13 as well as subcortical atrophy in the caudate and putamen, occur in HIV1 individuals with well-controlled immune status and systemic viral replication. 14 Other studies using CSF markers of inflammation such as neopterin 15 and markers of active axonal injury 16 also suggest ongoing CNS injury in HIV1 patients on cART. Thus, a clinical diagnosis of HAND may not be as sensitive as neuroimaging or CSF markers of CNS injury.
In a subset of individuals, approximately 13% showed clinical progression to more severe HAND. Risk factors for deterioration in clinical stage included hypercholesterolemia, suggesting that cerebrovascular disease could be contributing to some of the cognitive impairment seen in these HIV1 individuals. Genetic factors, variability in test measurements, or concomitant age-related contributors to CNS injury could lead to cognitive deterioration in these HIV1 individuals.
Several limitations should be noted. The MACS included gay/bisexual men and our results for HAND prevalence may not be applicable to other demographic groups of HIV1 individuals, especially women. Functional assessments (i.e., IADLs scale) were not performed in the MACS prior to 2007, so a diagnosis of HAND could not be applied prior to that time. Another limitation is that functional assessments other than the IADL scale are not available in the MACS to define functional impairment in the algorithm. Many of the MACS participants have seen the full neuropsychological test battery on multiple occasions. Thus, practice effects could have reduced the overall rate of prevalence of impairment or rate of neurocognitive progression. In addition, survivorship bias and loss to follow-up, which may be increased in HIV1 individuals with cognitive impairment, may result in an underestimation of the prevalence of HAND in the MACS. 17 Indeed, HIV1 individuals who did not attend all 3 time periods had an increased frequency of HAND in 2007-2008 compared to HIV1 individuals who did attend all 3 periods, and these HIV1 individuals may have been the most likely individuals to deteriorate in their HAND stage. In addition, although an attempt was made to exclude HIV1 individuals with contributing confounding conditions, cognitive impairment in the HAND cases could have been from comorbid conditions such as hypertension or diabetes.
Our study evaluated the temporal progression of HAND over a 4-year period. Future studies will need to evaluate longitudinal changes in HAND over a longer period of time to characterize the potential contribution of comorbid conditions as well as to determine whether markers of CNS injury observed in imaging studies are associated with changes in the clinical characteristics of HAND. Future studies also should evaluate performance and rates of progression in specific neurocognitive domains.
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